Mistletoe in Osteosarcoma – Upcoming Phase 2 Trial
European scientists and clinicians in the US from two pediatric oncology programs have developed the first study of Mistletoe or Viscum album extract in the US pediatric and young adult oncology populations with osteosarcoma cancers. This phase 2 trial is actively enrolling at two US sites with initiation of two additional sites in progress. This study is unique in its use of a naturally derived agent, not as complementary therapy, but as a primary anticancer agent for prevention of metastases. In clinical practice we have seen a trend with patients in support of this kind of trial in sarcoma cancers.
https://www.tandfonline.com/doi/full/10.1080/14796694.2026.2638986#d1e267
https://www.tiktok.com/@drlemmocancer/video/7623197194291514642